This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' CEO Chats: St. Jude Medical and Wyndham Worldwide

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Daniel Starks of St. Jude Medical (STJ - Get Report) and Stephen Holmes of Wyndham Worldwide (WYN - Get Report).

These are excerpts from Cramer's 'Mad Money' Recap, originally published on Feb. 7, 2014.

Executive Decision: Daniel Starks

For his "Executive Decision" segment, Cramer sat down with Daniel Starks, chairman and CEO of St. Jude Medical, a stock that was up 72% last year and hasn't given up any of its gains so far this year. St. Jude just posted a penny-a-share earnings beat on in-line revenue and guidance.

Starks showed off his company's new, revolutionary pacemaker, currently in clinical testing. The device, which is a fraction of the size of current pacemakers, can be implanted through a non-invasive procedure in as little as eight minutes, and the unit will last for up to 19 years. Starks said that in his opinion, once the device is available there will simply be no reason to choose anything else.

St. Jude currently controls nearly a quarter of the CRM, or cardiac rhythm management, market and its new device will only solidify that dominant position. St. Jude is also working on treatments for hypertension, particularly for patients who don't respond to other treatments.

With such revolutionary devices coming to market, Cramer asked Starks about some of his biggest hurdles. Starks noted that our country's current excise tax is a major stumbling block because St. Jude is a huge exporter of devices to patients around the globe.

Must Read: Jim Cramer's 'Mad Money' CEO Chats: Xilinx and Avnet

Cramer said that St. Jude clearly has game-changing technology.

Executive Decision: Stephen Holmes

In his "Executive Decision" segment, Cramer sat down with Stephen Holmes, chairman and CEO of Wyndham Worldwide, a stock that was down 2.8% [Feb. 7] on in-line earnings but is up an astounding 1,170%, including reinvested dividends, over the past five years.

Holmes said Wyndham had a great quarter, even better than expected. That hasn't translated to the stock price, however, which is up one day and down the next, he continued.

When asked about using declines to buy back stock, Holmes said Wyndham is always looking for weakness in the shares to buy back as many shares as it can.

Turning to the economy, Holmes said Wyndham is not seeing a slowdown in hotel construction. He said Obamacare is on the minds of many hotel operators, but hasn't caused any properties not to be developed. Instead, operators are simply staffing with fewer employees.

Finally, when asked about rival HomeAway (AWAY), Holmes said the two companies have different models, with Wyndham helping homeowners rent their properties as opposed to HomeAway's listing model.

Cramer reminded viewers that when stocks go down, sometimes it's a buying opportunity -- as it is in the case of Wyndham.


To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
STJ $68.69 -3.00%
WYN $75.14 -1.80%
AAPL $107.76 -4.40%
FB $87.23 -2.50%
GOOG $598.06 -3.30%

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs